# **GENERIC STEP THERAPY PLANS (GSTP)**

DRUG CLASS

### BISPHOSPHONATES

PGST SSB – Ref# 367-D: Binosto, Fosamax Plus D

HPGST SSB – Ref# 401-D: Binosto, Fosamax Plus D

TGST SSB – Ref# 377-D: Binosto, Fosamax Plus D

Status: CVS Caremark Criteria Type: Initial Step Therapy; Post Step Therapy Prior Authorization

#### **INITIAL STEP THERAPY**

If the patient has filled a prescription for at least a 28 day supply of at least one generic bisphosphonate within the past 365 days under a prescription benefit administered by CVS Caremark, then the requested branded drug will be paid under that prescription benefit. If the patient does not meet the initial step therapy criteria, then the system will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

#### COVERAGE CRITERIA

Branded bisphosphonates will be covered with post step therapy prior authorization when the following criteria are met:

• Patient has experienced an inadequate treatment response, intolerance, or contraindication to at least one generic bisphosphonate drug.

#### RATIONALE

If the patient has filled a prescription for at least a 28 day supply of at least one generic bisphosphonate within the past 365 days under a prescription benefit administered by CVS Caremark, then the requested branded drug will be paid under that prescription benefit.

If the patient does not meet the initial step therapy criteria, then prior authorization is required.

If the patient has a documented contraindication to or a potential drug interaction with a generic drug, then the requested brand drug will be covered. If the patient is intolerant to at least one of the generic drugs, then the requested brand drug will be covered. If the patient has tried one of the generic drugs for a sufficient trial and had an inadequate treatment response (as determined on most recent DEXA scan), then the requested brand drug will be covered. If these requirements are met, then the approval duration is 24 months.

#### **REFERENCES**

N/A

Written by: Date Written:	UM Development (NB) 11/2008
Revised:	12/2008, 02/2009, 09/2009, 10/2009. 07/2010, 01/2011, 05/2011, 01/2012 (removed Actonel w/ Calcium), 04/2012 (removed Boniva),
Reviseu.	
	07/2012 (removed Atelvia from PGST); 09/2012 (updated formatting and documentation), 10/2012 (added Binosto), 10/2013 (updated
	grids, re-worded question #2 & #3), 08/2014 (removed Actonel 150mg), 10/2014 (reordered questions, updated format), 07/2015
	(removed Actonel and Atelvia), 10/2015, 10/2016 (no changes) , (SF) 10/2017 (no changes)
Reviewed:	Medical Affairs (WF, MD) 12/2008, 02/2009, 09/2009, 10/2009, 07/2010, 01/2011, 01/2012, 04/2012, 07/2012; (DC) 09/2012, (LB)
	10/2012, (LS) 10/2013, (DC) 08/2014, (SS) 10/2014, 07/2015
External Review:	01/2009, 12/2009, 02/2011, 02/2012, 02/2013, 02/2014, 02/2015, 02/2016, 02/2017, 02/2018

## **CRITERIA FOR APPROVAL**

#### 1 Has the patient demonstrated an inadequate treatment response (as determined on most

GSTP Bisphosphonates COMM 10-2017 (1)

© 2016 Caremark. All rights reserved. This document contains confidential, privileged and proprietary information of CVS/caremark. It cannot be reproduced, distributed or printed without written permission from CVS/caremark. Clinical criteria may change at any time based on at-risk generic launches, new drug approvals, formulary changes and other market and regulatory events. Updates to the clinical criteria and GSTP may be made quarterly. This page contains prescription brand name drugs that are registered or trademarks of pharmaceutical manufacturers that are not affiliated with CVS/caremark Inc.



Yes

No

# **CVS**/caremark<sup>®</sup>

	recent DEXA scan) after a sufficient trial of a generic bisphosphonate? [If yes, then no further questions.]		
2	Does the patient have a documented contraindication to or a potential drug interaction with a generic bisphosphonate? [If yes, then no further questions.]	Yes	No
3	Has the patient had a trial and was intolerant to at least one generic bisphosphonate?	Yes	No

Guidelines for Approval							
	Duration of Appro	oval		24 Months			
Set 1 - Failed Trial		Set 2 – Contrair	Set 2 – Contraindication		Set 3 – Intolerant		
Yes to question(s)	No to question(s)	Yes to question(s)	No to question(s)	Yes to question(s)	No to question(s)		
1	None	2	1	3	1		
					2		

Mapping Instructions					
	Yes	No			
1	Approve for 24 months	Go to 2			
2	Approve for 24 months	Go to 3			
3	Approve for 24 months	Deny			

GSTP Bisphosphonates COMM 10-2017 (1)

© 2017 Caremark. All rights reserved. This document contains confidential, privileged and proprietary information of CVS/caremark. It cannot be reproduced, distributed or printed without written permission from CVS/caremark. Clinical criteria may change at any time based on at-risk generic launches, new drug approvals, formulary changes and other market and regulatory events. Updates to the clinical criteria and GSTP may be made quarterly. This page contains prescription brand name drugs that are registered or trademarks of pharmaceutical manufacturers that are not affiliated with CVS/caremark Inc.

